Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9168337 | 0.79 | PPARG (0.65) | PPARGAGTR1AGTR2 | |
| SCHEMBL7308562 | 0.79 | AGTR1 (0.47) | AGTR1AGTR2 | |
| SCHEMBL7304485 | 0.78 | AGTR1 (0.53) | AGTR1 | |
| SCHEMBL8845238 | 0.78 | AGTR1 (0.46) | AGTR1AGTR2 | |
| SCHEMBL7312391 | 0.77 | AGTR1 (0.46) | AGTR1AGTR2 | |
| SCHEMBL1970345 | 0.77 | AGTR1 (0.61) | AGTR1AGTR2 | |
| SCHEMBL7310118 | 0.76 | AGTR1 (0.54) | AGTR1AGTR2 | |
| Water SCHEMBL2576561 | 0.76 | AGTR1 (0.60) | AGTR1AGTR2 | |
| SCHEMBL3342427 | 0.76 | AGTR1 (0.60) | AGTR1AGTR2 | |
| SCHEMBL7303268 | 0.75 | AGTR1 (0.49) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076492-B2 | Process for preparing trityl olmesartan medoxomil and olmesartan medoxomil | CIPLA LIMITED (IN) | 2011-12-13 | — | — | US | disclosed |
| US-20100160643-A1 | Process for Preparing Trityl Olmesartan Medoxomil and Olmesartan Medoxomil | CIPLA LIMITED (IN) | 2010-06-24 | — | — | US | disclosed |
| EP-2074116-A2 | PROCESS FOR PREPARING TRITYL OLMESARTAN MEDOXOMIL AND OLMESARTAN MEDOXOMIL | Cipla Limited (IN) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008043996-A2 | PROCESS FOR PREPARING TRITYL OLMESARTAN MEDOXOMIL AND OLMESARTAN MEDOXOMIL | CIPLA LIMITED (IN) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160643-A1 | Process for Preparing Trityl Olmesartan Medoxomil and Olmesartan Medoxomil | MED1, AGTR1, MED12 | PPARG 1292/4885AGTR1 2/4885AGTR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.